Get the Stockscreener App
1.55
1.84%
0.028
After Hours:
1.55
NanoViricides Inc stock is traded at $1.55, with a volume of 505.54K.
It is up +1.84% in the last 24 hours and up +16.54% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.522
Open:
$1.64
24h Volume:
505.54K
Relative Volume:
0.56
Market Cap:
$35.62M
Revenue:
-
Net Income/Loss:
$-8.09M
P/E Ratio:
-3.5599
EPS:
-0.4354
Net Cash Flow:
$-7.37M
1W Performance:
+0.65%
1M Performance:
+16.54%
6M Performance:
+60.87%
1Y Performance:
-1.90%
1-Day Range:
$1.51
$1.67
1-Week Range:
$1.45
$1.67
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.55 | 35.39M | 0 | -8.09M | -7.37M | -0.4354 |
VRTX
Vertex Pharmaceuticals Inc
|
470.72 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
759.24 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.79 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.45 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
313.77 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Ebola outbreak death toll tops 1,300 as drug trial awaits approval - Stock Titan
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Inc (NNVC) Cash Flow - TradingKey
EDGAR Filing Documents for 0001104659-26-086797 - SEC.gov
Form 424B5 NanoViricides Inc For: 27 July By Investing.com - Investing.com Canada
Form 424B5 NANOVIRICIDES, INC. - StreetInsider
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - ACCESS Newswire
NanoViricides, Inc. Revenue Breakdown – AMEX:NNVC - TradingView
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NNVC|NanoViricides Inc|Price:1.535|Chg%:+0.055 - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Raises $3.8 Million in Registered Direct Offering to Fund Antiviral Drug Development - citybuzz -
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - Lelezard
NanoViricides prices offering with 2,516,339 warrants at US$ 1.75 exercise price - Bitget
NanoViricides Seeks Approval for Phase II Ebola Trial in DRC Amid Ongoing Outbreak - citybuzz -
NanoViricides (NYSE:NNVC) Draws Attention After Clinical Update - Kalkine Media
DRC Ebola outbreak tops 930 deaths; NanoViricides seeks trial approval - Stock Titan
Nanoviricides Company Profile & Introduction - Moomoo
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Pre-Revenue StageProfit Announcement - dars.gov.et
Form 424B5 NanoViricides Inc For: 17 July By Investing.com - Investing.com South Africa
Form 424B5 NanoViricides Inc For: 17 July - Investing.com UK
NanoViricides Establishes ATM Equity Sales Agreement - TipRanks
NanoViricides Inc. (NNVC) Q2 2026 Earnings: Narrowed Loss Beats Expectations; Stock RisesROE Trend Analysis - dars.gov.et
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Treasure Coast News
Noble Financial Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Treasure Coast News
NanoViricides Secures Ethics Approval for Phase II Ebola Trial in DRC - citybuzz -
As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo - ACCESS Newswire
Oral Ebola drug gummies clear key ethics hurdle as Congo outbreak widens - Stock Titan
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
NanoViricides Receives Outperform Rating and $6 Price Target from Noble Capital Markets - citybuzz -
NanoViricides Inc. (NNVC) Q2 2026 Earnings: EPS Beat but No Revenue; Stock Declines 1.01%Earnings Revision Upgrade - dars.gov.et
Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily - ACCESS Newswire
symbol__ Stock Quote Price and Forecast - CNN
NanoViricides Price Target Announced at $6.00/Share by Noble Capital Markets - Moomoo
Noble Capital initiates NanoViricides stock with Outperform rating By Investing.com - Investing.com South Africa
Noble Financial Initiates Nanoviricides(NNVC.US) With Buy Rating, Announces Target Price $6 - Moomoo
NanoViricides Advances NV-387 Oral Gummies Toward Phase II Trial for Bundibugyo Ebola in DRC - citybuzz -
Noble Capital initiates NanoViricides stock with Outperform rating - Investing.com
As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo - ACCESS Newswire
NanoViricides moves NV-387 oral gummies toward DRC Ebola trial - Stock Titan
Enterprise value to revenue forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVCNanoViricides Inc Website Traffic and Mobile Apps Usage - Finviz
Price to book forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
Enterprise value to revenue forward of NanoViricides, Inc. – SWB:NV3P - TradingView
Enterprise value to EBITDA forward of NanoViricides, Inc. – AMEX:NNVC - TradingView
NNVC Q2 2026 Earnings: Narrower-than-Expected Loss as R&D Pipeline AdvancesEarnings Cycle Report - po-news-eg.net
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.84%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):